StockNews.AI
PHAR
StockNews.AI
168 days

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

1. Pharming's EGM approved Mr. Fabrice Chouraqui as new CEO. 2. Outgoing CEO Sijmen de Vries will advise until December 2025. 3. Shareholders also approved Chouraqui's remuneration package. 4. Pharming focuses on treating rare diseases with innovative therapies. 5. Leadership change aims to strengthen Pharming's market position.

4m saved
Insight
Article

FAQ

Why Bullish?

Leadership changes typically instill fresh vision and strategies, positively impacting stock performance.

How important is it?

Leadership change is critical for strategic direction and investor confidence in growth potential.

Why Short Term?

Changes in leadership often lead to stock price reactions within weeks or months.

Related Companies

AMGNREGNGILD
Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years. As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of tasks and responsibilities, Mr. de Vries will remain a strategic advisor to the new CEO until December 31, 2025. In addition, shareholders also approved the proposal to approve certain components of the remuneration package of Mr. Chouraqui in his capacity as Executive Director and Chief Executive Officer. A recording of the webcast, presentation slides from today’s EGM, and more details regarding both agenda items are available on the Pharming website in the Investor Relations section. Dr. Richard Peters, Chairman of the Board of Directors, commented:“On behalf of the entire Board, we welcome Fabrice Chouraqui as our new Executive Director and Chief Executive Officer and we look forward to working with him to deliver on Pharming’s objectives and to further strengthen the company’s position in the rare disease market. We would also like to thank our outgoing Chief Executive Officer, Sijmen de Vries, for his significant accomplishments and leadership over the past 16 years and for remaining as strategic advisor through year end.” About Pharming Group N.V.  Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit www.pharming.com and find us on LinkedIn.   Inside InformationThis press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. For further public information, contact:Pharming Group, Leiden, the NetherlandsMichael Levitan, VP Investor Relations & Corporate CommunicationsT: +1 (908) 705 1696E: investor@pharming.com FTI Consulting, London, UKSimon Conway/Alex Shaw/Amy ByrneT: +44 203 727 1000 LifeSpring Life Sciences Communication, Amsterdam, the NetherlandsLeon MelensT: +31 6 53 81 64 27E: pharming@lifespring.nl Pharming EGM 2025 PR_EN_04MAR25

Related News